bioAffinity Technologies, Inc. (BIAF) Stock Analysis & Investment Frameworks
bioAffinity Technologies, Inc. (BIAF) stock analysis on Invetso. Review bioAffinity Technologies, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
bioAffinity Technologies, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Medical - Diagnostics & Research
- Country: US
bioAffinity Technologies, Inc. Key Financial Metrics
- Market Cap: $3.33M
- Revenue: $6.16M
- ROE: -257.27%
- ROIC: -237.93%
- Dividend Yield: N/A
About bioAffinity Technologies, Inc.
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
bioAffinity Technologies, Inc. Investment Frameworks
Invetso analyzes bioAffinity Technologies, Inc. (BIAF) across the following frameworks:
- bioAffinity Technologies, Inc. 10Y Growth Potential
- bioAffinity Technologies, Inc. Scenario Analysis
- bioAffinity Technologies, Inc. Risks & Opportunities
- bioAffinity Technologies, Inc. Economic Moat
- bioAffinity Technologies, Inc. Business Model
- bioAffinity Technologies, Inc. Management
- bioAffinity Technologies, Inc. SWOT Analysis
- bioAffinity Technologies, Inc. Porter's 5 Forces
- bioAffinity Technologies, Inc. PESTLE Analysis
- bioAffinity Technologies, Inc. ESG Analysis
